A substantial decrease in Medicare spending as a result of improvements made by the Affordable Care Act (ACA)will result in the Medicare Trust Fund lasting until 2030.
FDA has approved Iroko Pharmaceuticals’ Tivorbex (indomethacin), a low-dose painkiller for adult patients.
A federal appeals court has struck down subsidies provided under the Affordable Care Act (ACA) for federally run insurance exchanges.
The Society for Clinical Research Sites (SCRS) and TransCelerate BioPharma Inc. have launched the Site Advocacy Group (SAG), an initiative that enables clinical investigators and site professionals to interact directly with senior industry leaders in the exchange of perspectives and experiences on innovative ideas, processes, tools and technologies.
The Advisory Committee on Immunization Practices voted 15 to 0 to recommend a preference for the inhaled live attenuated influenza vaccine, FluMist Quadrivalent, for healthy children ages 2 years through 8 years.
The U.S. Food and Drug Administration has approved HYQVIA (Immune Globulin Infusion 10% [Human] with Recombinant Human Hyaluronidase), Baxter’s subcutaneous treatment for adult patients with primary immunodeficiency.
The U.S. Food and Drug Administration (FDA) has approved PharmaJet Inc.’s Stratis 0.5mL Needle-Free Jet Injector for delivery of bioCSL Inc.’s AFLURIA influenza vaccine for individuals ages 18 to 64 years.
Under a proposed rule by the Centers for Medicare and Medicaid Services(CMS), healthcare providers will have an extra year to use 2011 edition software in their electronic health record systems under the federal incentive program for health IT.
To evaluate the effect of intravenous immune globulin (IVIG) on cardiac rhythm and function in children younger than 12 years of age presenting with acute myocarditis and/or early dilated cardiomyopathy (DCM), investigators at a tertiary hospital in India conducted a retrospective analysis of case records between January 2010 and December 2012.
CSL Behring has enrolled its first patient in the pivotal pediatric PhaseIII study to evaluate the efficacy, safety and pharmacokinetics of its novel investigational recombinant factor VIII single chain (rVIII-SingleChain) for the treatment of previously treated children (up to 11 years) with severe hemophilia A.
The National Institutes of Health began human testing of an ebola vaccine in a Phase I clinical trial in September.
The Centers for Disease Control and Prevention found that vaccination coverage among adolescents ages 13 to 17 years rose between 2012 and 2013.
